CoxaPro
> Clinical Library > Welcome to the joint replacement clinical library > Age and Frailty Influence Hip and Knee Arthroplasty Reimbursement in a Bundled Payment Care Improvement Initiative
The Journal of Arthroplasty, Volume 34, Issue 7, S80 - S83
Hip Knee
Link to article
Age and Frailty Influence Hip and Knee Arthroplasty Reimbursement in a Bundled Payment Care Improvement Initiative
Pepper, Andrew M. et al.Hip Knee
Background
The Bundled Payment Care Improvement (BPCI) initiative aims to improve quality of patient care while mitigating cost. How patient age and frailty affect reimbursement after hip and knee total joint arthroplasty (TJA) is not known. This study evaluates if patient age and frailty affect cost of care.
Methods
A retrospective review of prospectively collected data of 1821 patients undergoing TJA at our institution under the BPCI initiative was performed from 2013 to 2016. We recorded demographics for patients and calculated their modified frailty index (mFI). Cost of care was obtained for each patient. Statistical analyses included t-test and analysis of variance to evaluate age and frailty as independent categorical variables. Beta coefficients were utilized to evaluate age as a continuous variable. Multivariate linear regression models evaluated age and frailty’s combined contribution to cost.
Results
Age was evaluated as a categorical variable, with the median age of our sample population the categorical cutoff. Age ≥72 years and increasing mFI score were associated with statistically significant increased cost. Increasing age demonstrated a statistically significant increase in cost of 0.68% per incremental age increase. Multivariate evaluation of increasing age and mFI revealed a statistically significant increase in cost for mFI score ≥2.
Conclusion
Increasing age and frailty increase cost associated with TJA. The BPCI initiative over-simplifies the cost associated with TJA. Concerningly, this information could deincentivize care to older, higher risk patients. Objective patient-specific and risk-adjusted stratification of BPCI pricing is necessary to be considered as a valid financial model.
Link to article